Share on StockTwits

Stemline Therapeutics (NASDAQ:STML) announced its earnings results on Friday. The company reported ($0.47) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.71) by $0.24, StockRatingsNetwork.com reports.

Shares of Stemline Therapeutics (NASDAQ:STML) opened at 11.52 on Friday. Stemline Therapeutics has a one year low of $10.68 and a one year high of $47.25. The stock’s 50-day moving average is $12.61 and its 200-day moving average is $17.6. The company’s market cap is $148.6 million.

On the ratings front, analysts at Jefferies Group cut their price target on shares of Stemline Therapeutics from $60.00 to $50.00 in a research note on Monday, May 19th. They now have a “buy” rating on the stock. One research analyst has rated the stock with a sell rating and five have given a buy rating to the company’s stock. Stemline Therapeutics presently has an average rating of “Buy” and a consensus price target of $53.25.

Stemline Therapeutics, Inc (NASDAQ:STML) is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics that target both cancer stem cells (CSCs) and tumor bulk.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.